USA: A new study has revealed that among children with newly diagnosed immune thrombocytopenia needing pharmacologic ...

Over the past six decades, anti-thrombotic drug therapies have undergone a revolution, leading to major improvements in ...

The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+/HER2– breast cancer, offering a new targeted first-line ...

Rigel Pharmaceuticals, Inc. posted a solid Q3 with robust sales growth. Discover insights on future profitability and market ...

Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to ...

Rising global incidence of myeloproliferative diseases boosts demand for specialized treatments. Breakthroughs in JAK inhibitors and thrombopoietin receptor agonists enhance disease management. The ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Leonurus japonicas Houtt., a medicinal herb with a history dating back to the ancient classical text Shennong Bencao Jing—where it was noted for ...

Bristol Myers Squibb today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell ...

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve ...

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

Crosstalk between pattern recognition receptors (PRRs) expressed by dendritic cells orchestrates T helper (T H) cell differentiation through the induction of specific cytokine expression profiles, ...